Cell Source, Inc.

CLCS ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017
Operating Activities
Net Income $-4.5M $-5.3M $-5.2M $-5.5M $-4.6M $-4.5M $-2.1M $-3.1M
Depreciation & Amortization — — — — — — — —
Depreciation — — — — — — $0 $407
Amortization — — — — — — — —
Stock-Based Compensation — — $77.9K $419.4K $791.7K $844.1K $-22.5K $44.7K
Net Cash from Operating Activities $-2.7M $-2.3M $-3.1M $-3.4M $-2.8M $-2.6M $-2.0M $-2.3M
Investing Activities
Capital Expenditures — — — — — — — —
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities — — — — — — — —
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $2.7M $2.1M $3.3M $3.2M $3.0M $2.6M $1.7M $2.7M
Net Change in Cash $52.4K $-200.5K $129.6K $-152.0K $217.2K $9.0K $-352.1K $367.3K
Free Cash Flow — — — — — — — —
← Newer Page 1 of 2 Older →